Bcg Administration
Bcg Administration - Related Videos
06:32
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
0 Views •
Cited by 14 •
2016
We herein detail the methodology followed to compare protective efficacy and lung immune response induced by intranasal and subcutaneous immunization with BCG in mouse model. Our results show the benefits of pulmonary vaccination and suggest a role for IL17-mediated response in vaccine-induced protection.
02:16
Intranasal Immunization with BCG in a Mouse Model
0 Views •
2025
This video demonstrates intranasal BCG immunization in mice, activating both innate and adaptive immune responses, leading to the development of lung-resident memory T cells and effector B cells, thus enhancing protection against Mycobacterium infections.
08:10
A Functional Whole Blood Assay to Measure Viability of Mycobacteria, using Reporter-Gene Tagged BCG or M.Tb (BCG lux/M.Tb lux)
0 Views •
Cited by 19 •
2011
We describe an alternative approach to the enumeration of mycobacteria in vitro, which uses reporter-gene tagged mycobacteria instead of colony-forming units (CFU). “Survival” of organisms as well as host response-markers are measured simultaneously, providing a low-cost, versatile and functional system for studies of host/pathogen interactions in the context of tuberculosis.
04:06
Preparation and Quantification of Mycobacterium bovis BCG lux Inoculum for Infection
0 Views •
2025
This video demonstrates the preparation and quantification of Mycobacterium bovis Bacillus Calmette-Guérin lux inoculum using bioluminescence assay and the enumeration of colony-forming units. The prepared inoculum can be used for infection studies.
03:12
An Avidin-Biotin Conjugation Technique for Presenting Target Antigens on Mycobacterium bovis BCG
0 Views •
2025
The video demonstrates a technique for loading antigens on Mycobacterium bovis BCG to improve its immunogenic properties. The method uses the avidin-biotin system to coat the bacterial surface with exogenous antigens.
FAQs
After intradermal delivery, antigen-presenting cells recognize mycobacterial components and initiate immune activation. Their signaling supports the development of cellular immunity, including T-cell responses, which is central to the protective effect studied in tuberculosis prevention. This mechanism also provides a framework for examining how vaccination shapes host responses to infection.
The route determines where immune stimulation is concentrated and therefore supports different objectives. Intradermal administration is associated with protective immunity research for tuberculosis, whereas intravesical delivery directs BCG-related inflammation to the bladder for cancer treatment. Comparing these routes helps investigators distinguish tissue-specific immune effects from broader vaccine-induced responses.
BCG administration can serve as a model for studying more than antigen-specific protection. Its research uses include vaccine-induced immunity, trained innate responses, and host-pathogen interactions. Trained innate responses refer to altered readiness of innate immune cells after an earlier stimulus. Studying these effects can clarify how BCG shapes later immune behavior.
Reliable administration depends on matching the route and dose to the intended use, followed by appropriate monitoring. For tuberculosis prevention, the procedure uses intradermal injection; bladder cancer treatment uses intravesical instillation. Observation for adverse reactions is important because the goal is to obtain useful immune activation without allowing treatment-related effects to go unchecked.
In tuberculosis-related work, BCG administration is used to study protective immune responses, particularly cellular and T-cell activity. In bladder cancer treatment, intravesical delivery is used to provoke local antitumor inflammation. These applications place the same immunological stimulus in different clinical contexts, allowing researchers to examine prevention and therapeutic immune mechanisms separately.
Researchers interpret outcomes by considering the response sought: cellular immunity and T-cell activity in tuberculosis-related work, or local antitumor inflammation in bladder cancer studies. They can also examine trained innate responses and host-pathogen interactions. This outcome-based view prevents a single immune readout from being treated as evidence of every possible effect.